in vivo News and Research

RSS

New mechanism of bone formation may help fight osteoporosis

The natural cycle of building bone to maintain skeletal strength and then breaking it down for the body's calcium needs is delicately balanced, but diseases like osteoporosis break down too much bone without adequate bone replacement, leading to bone fractures.

8 Oct 2009

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

Researchers at The Wistar Institute have identified a key gene (KLF17) involved in the spread of breast cancer throughout the body. They also demonstrated that expression of KLF17 together with another gene (Id1) known to regulate breast cancer metastasis accurately predicts whether the disease will spread to the lymph nodes.

6 Oct 2009

NIH awards Galenea a Challenge Grant for developing predictive in vivo models of cognition

Galenea Corp., a fully-integrated CNS drug discovery company, announced today that it has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009 (Recovery Act). This two-year grant from the National Institute of Mental Health addresses the specific topic of "Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders" within the challenge area of Translational Science.

6 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

Retinoic acid may provide relief for ulcerative colitis

Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases.

3 Oct 2009

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

VeriChip Corporation and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing development partnership with RECEPTORS to launch Phase II development of an in vivo glucose-sensing RFID microchip.

1 Oct 2009

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Invivo Corporation introduces advanced clinical prostate visualization system

The introduction of Invivo Corporation's DynaCAD for Prostate advanced clinical visualization and MR interventional system brings new hope to patients and new confidence to their care providers, a positive development this Prostate Cancer Awareness Month.

1 Oct 2009

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

1 Oct 2009

Grants to research GanedenBC30 probotic effect on human immune cells

Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators.

1 Oct 2009

VeriChip and Optimus sign definitive agreement

VeriChip Corporation ("VeriChip" or the "Company") today announced it has entered into a definitive agreement for a $10,000,000 investment commitment with Optimus Technology Capital Partners, LLC, or Optimus.

30 Sep 2009

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world’s first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that successful results of an acute in vivo study of its TMVI system were disclosed by Dr. Joseph Bavaria during the “Mitral Valve Therapies Prior to and in Human Investigation” program at the “Transcatheter Cardiovascular Therapeutics (TCT) 2009” annual scientific meeting on Friday.

28 Sep 2009

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has recently acquired direct ownership of technology for which it had previously exercised its option to exclusively license from Advirna LLC.

25 Sep 2009

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced a series of XenoLight Rediject reagents at the World Molecular Imaging Congress (WMIC) in Montreal, Canada. Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents for Caliper's IVIS optical imaging systems.

25 Sep 2009

Chronic sleep deprivation linked to early incidence of Alzheimer's brain plaques

Chronic sleep deprivation in a mouse model of Alzheimer's disease makes Alzheimer's brain plaques appear earlier and more often, researchers at Washington University School of Medicine in St. Louis report online this week in Science Express.

25 Sep 2009

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

Oncolytics Biotech Inc. announced today that the Cancer Therapy Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic melanoma.

24 Sep 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

23 Sep 2009

in vivo News and Research

New mechanism of bone formation may help fight osteoporosis

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

NIH awards Galenea a Challenge Grant for developing predictive in vivo models of cognition

Preclinical study results of AVL-181 protease inhibitor presented

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Retinoic acid may provide relief for ulcerative colitis

VeriChip to commence Phase II development of an in vivo glucose-sensing RFID microchip

New molecular imaging technique raises hope for common malignant female tumor

Invivo Corporation introduces advanced clinical prostate visualization system

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

Grants to research GanedenBC30 probotic effect on human immune cells

VeriChip and Optimus sign definitive agreement

Preclinical data of CardiAQ Valve Technologies' TMVI in vivo study presented at the TCT 2009

RXi Pharmaceuticals acquires self-delivering rxRNA technology platform from Advirna

Current stem cell applications to be discussed at NJIT

Caliper Life Sciences unveils XenoLight Rediject reagents series at WMIC

Chronic sleep deprivation linked to early incidence of Alzheimer's brain plaques

CTRC commences patient enrolment in Phase 2 clinical trial of REOLYSIN for metastatic melanoma

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News